POST-CABGDM: Empagliflozin in Perioperative CABG
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 155 participants.
Also called NCT04523064
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 155 participants
- Registry
-
NCT04523064
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT04523064. Randomized; no masking; primary purpose treatment. Start 2020-09-22 (actual); primary completion 2024-01-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- POST-CABGDM: Empagliflozin in Perioperative CABG
- Acronym
- POST-CABGDM
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Coronary Artery Disease
- Condition
- Coronary Artery Bypass Surgery
- Condition
- Acute Kidney Injury
- Intervention (Drug)
- Empagliflozin 25 MG
- Lead sponsor
- University of Sao Paulo General Hospital
Record details
- Record id
cardio:ct-nct04523064- Content hash
d8b5a84f684ef7d0b7a980f41bda1452d4a4236deb26b2437ff962821b6d1b41